PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16422308

Group sequential methods for cluster randomization trials with binary outcomes.

Guang Yong Zou·Allan Donner·Neil Klar
View original source ↗Export metadata ↓

Abstract

BACKGROUND: Cluster randomization trials in which intact social units are randomly assigned to different intervention groups have become very popular in recent years, particularly for the evaluation of innovations in the delivery of health care. An extensive literature dealing with the associated methodological challenges has also appeared. Although the monitoring of such trials using formal stopping rules is clearly indicated when the outcomes are irreversible and individual-level data are available sequentially, simple and reliable statistical methods that may be used for this purpose are currently not available. PURPOSE: To investigate the validity of standard group sequential methods when applied to cluster randomization trials having binary outcomes. METHODS: The large sample distributions for each of five test statistics computed from sequentially accumulated data are derived. A simulation study is performed to evaluate the finite sample properties of these statistics when applied to the interim analysis of cluster randomization trials. Data from the World Health Organization antenatal care trial are used to illustrate the methods. RESULTS: Each of the joint distributions is shown to be characterized by a covariance structure that asymptotically satisfies an independent increments structure, a foundation that simplifies group sequential methods. The simulation study reveals that four of the five test statistics evaluated provide satisfactory performance with as few as 10 clusters allocated to each of two interventions. LIMITATIONS: The applicability of our results to effect estimation following a group sequential cluster randomization trial is not investigated, although a theoretical foundation which may be used for this purpose is presented. CONCLUSIONS: Standard group sequential methods can be applied to cluster randomization trials when interim analyses are warranted.

Explore related subjects

Clinical Trials as TopicComputer SimulationData Interpretation, StatisticalFemaleHumansPregnancyPrenatal CareRandomized Controlled Trials as TopicResearch DesignSample SizeStatistics as TopicWorld Health OrganizationJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Guang Yong Zou, Allan Donner, Neil Klar. 2005. Group sequential methods for cluster randomization trials with binary outcomes.. https://doi.org/10.1191/1740774505cn126oa

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Estimation in flexible two stage designs.

Adaptive test designs for clinical trials allow for a wide range of data driven design adaptations using all information gathered until an interim analysis. The basic principle is to use a test statistics which is invariant with respect to the design adaptations under the null hypothesis. This allows for a control of the type I error rate for the primary hypothesis even for adaptations not specified a priori in the study protocol. Estimation is usually another important part of a clinical trial, however, is more difficult in adaptive designs. In this research paper we give an overview of point and interval estimates for flexible designs and compare methods for typical sample size rules. We also make some proposals for confidence intervals which have nominal coverage probability also after an unforeseen design adaptation and which contain the maximum likelihood estimate and the usual unadjusted confidence interval.

Clinical Trials as Topic↗
PubMed2006

Operating characteristics of sample size re-estimation with futility stopping based on conditional power.

Various methods have been described for re-estimating the final sample size in a clinical trial based on an interim assessment of the treatment effect. Many re-weight the observations after re-sizing so as to control the pursuant inflation in the type I error probability alpha. Lan and Trost (Estimation of parameters and sample size re-estimation. Proceedings of the American Statistical Association Biopharmaceutical Section 1997; 48-51) proposed a simple procedure based on conditional power calculated under the current trend in the data (CPT). The study is terminated for futility if CPT < or = CL, continued unchanged if CPT > or = CU, or re-sized by a factor m to yield CPT = CU if CL < CPT < CU, where CL and CU are pre-specified probability levels. The overall level alpha can be preserved since the reduction due to stopping for futility can balance the inflation due to sample size re-estimation, thus permitting any form of final analysis with no re-weighting. Herein the statistical properties of this approach are described including an evaluation of the probabilities of stopping for futility or re-sizing, the distribution of the re-sizing factor m, and the unconditional type I and II error probabilities alpha and beta. Since futility stopping does not allow a type I error but commits a type II error, then as the probability of stopping for futility increases, alpha decreases and beta increases. An iterative procedure is described for choice of the critical test value and the futility stopping boundary so as to ensure that specified alpha and beta are obtained. However, inflation in beta is controlled by reducing the probability of futility stopping, that in turn dramatically increases the possible re-sizing factor m. The procedure is also generalized to limit the maximum sample size inflation factor, such as at m max = 4. However, doing so then allows for a non-trivial fraction of studies to be re-sized at this level that still have low conditional power. These properties also apply to other methods for sample size re-estimation with a provision for stopping for futility. Sample size re-estimation procedures should be used with caution and the impact on the overall type II error probability should be assessed.

Clinical Trials as Topic↗
PubMed2006

Conditional power calculations for clinical trials with historical controls.

A trial of a new therapy is to be compared to results from a previous trial of patients treated with a standard therapy. For a given sample size for the trial of the new therapy, we desire the power, against a specific alternative hypothesis, for the hypothesis test of the null hypothesis that the therapies are equivalent. Alternatively, the sample size required for the trial of the new therapy is needed for a target power. We explain why a popular method for doing these calculations is wrong, and discuss alternative methods in the context of normal outcomes, binary outcomes, and time-to-event outcomes.

Clinical Trials as Topic↗